PDCD1 and neoplasm: Importantly, in models that were partially responsive or nonresponsive to anti–programmed cell death protein 1 (PD-1) therapy, combination therapy with SC or oral MK-2118 plus anti–PD-1 therapy resulted in greater inhibition of tumor growth and prolongation of survival compared with either agent alone (7).